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Background: The dose of mifepristone approved by most government agencies for medical abortion is 600 mg. Our aim was to summarize
extant data on the effectiveness and safety of regimens using the widely recommended lower mifepristone dose, 200 mg, followed by
misoprostol in early pregnancy and to explore potential correlates of abortion failure.
Study Design: To identify eligible reports, we searched Medline, reviewed reference lists of published reports, and contacted experts to
identify all prospective trials of any design of medical abortion using 200 mg mifepristone followed by misoprostol in women with
viable pregnancies up to 63 days' gestation. Two authors independently extracted data from each study. We used logistic regression
models to explore associations between 15 characteristics of the trial groups and, separately, the rates of medical abortion failure and of
ongoing pregnancy.
Results: We identified 87 trials that collectively included 120 groups of women treated with a regimen of interest. Of the 47,283 treated
subjects in these groups, abortion outcome data were reported for 45,528 (96%). Treatment failure occurred in 2,192 (4.8%) of these
evaluable subjects. Ongoing pregnancy was reported in 1.1% (499/45,150) of the evaluable subjects in the 117 trial groups reporting this
outcome. The risk of medical abortion failure was higher among trial groups in which at least 25% of subjects had gestational age N8 weeks,
the specified interval between mifepristone and misoprostol was less than 24 h, the total misoprostol dose was 400 mcg (rather than higher),
or the misoprostol was administered by the oral route (rather than by vaginal, buccal, or sublingual routes). Across all trials, 119 evaluable
subjects (0.3%) were hospitalized, and 45 (0.1%) received blood transfusions.
Conclusions: Early medical abortion with mifepristone 200 mg followed by misoprostol is highly effective and safe.
© 2013 Elsevier Inc. All rights reserved.Keywords: Medical abortion; Mifepristone; Misoprostol; Systematic review1. Introduction
Since mifepristone was introduced in France and China
more than two decades ago, medical abortion with this
antiprogestin has expanded rapidly throughout the world.
Mifepristone is now registered in 50 countries (www.
gynuity.org, accessed 14 December 2011). In the United
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http://dx.doi.org/10.1016/j.contraception.2012.06.011performed medically [1], and in several countries in Europe,
the proportion exceeds 60% [2,3].
Although medical abortion regimens approved by most
government regulatory agencies specify 600 mg mifepristone,
in practice, a dose of 200 mg is standard worldwide [4–7].
A prostaglandin, misoprostol, is administered after the
mifepristone to enhance success. The dose, route, and timing
of administration of misoprostol are not standardized. In the
United States, affiliates of Planned Parenthood Federation of
America provide 800 mcg buccally 24–48 h after the
mifepristone [4]. The International Federation of Obstetricians
and Gynaecologists recommends either vaginal, buccal, or
sublingual administration [5] as do the World Health
Organization [6] and the United Kingdom Royal College of
Obstetricians and Gynaecologists [7], which also recommend
27E.G. Raymond et al. / Contraception 87 (2013) 26–37oral dosing at gestational ages up to 49 days. Lower doses,
divided doses, oral administration, and a shorter or longer
interval between the two drugs also have been used clinically
or evaluated in research studies.
The purpose of this review is to summarize published data
on the effectiveness and safety of regimens including 200 mg
mifepristone followed by misoprostol for early medical
abortion. We also explore whether variation among studies
in the frequency of medical abortion failure could be
explained by characteristics of the study designs, treatment
protocols, or study populations.2. Materials and methods
We searched Medline using PubMed on 7 July 2011 for
studies of medical abortion using mifepristone and miso-
prostol. Our search strategy was as follows: (abortion OR
pregnancy termination OR termination of pregnancy) AND
(mifepristone OR RU 486 OR RU-486 OR RU486 OR
Mifegyne OR Mifeprex OR Medabon) AND (misoprostol
OR prostaglandin). In addition, we reviewed the reference
lists of relevant articles, and we contacted experts in the field
for information about any published or unpublished trials not
discovered in our search.
Two authors (E.G.R., C.S.) independently examined the
search results (titles and as necessary abstracts and full
publications) and other available information to identify all
English language reports of prospective trials that included
at least one group of women with viable first trimester
pregnancies who were treated with a specified abortion
regimen consisting of 200 mg mifepristone followed by
misoprostol. These trials included randomized trials, cohort
studies, and case series studies. For each group of interest
in these reports, the same two authors separately abstracted
data, including information about the study design and
treatment protocol, the number and characteristics of
women treated, and the numbers who had medical abortion
failure, medical abortion failure with a diagnosed ongoing
(viable) pregnancy, hospitalization, and blood transfusion.
We contacted some authors to obtain additional data or to
clarify details about the studies. We resolved discrepancies
by discussion.
In some reports, the effectiveness analyses excluded
subjects who initiated treatment but failed to complete the
full prescribed medical abortion regimen. Our analyses
included all pregnant women in each trial group who
received at least mifepristone and who had a gestational age
of 63 days or less, were not known to have an ectopic
pregnancy, and had a reported abortion outcome. Most trials
defined medical abortion failure as need for surgical
intervention to complete the abortion, but a few used other
definitions, such as failure to abort within 24 h after the
misoprostol [8] and use of additional abortifacient drugs after
the initially prescribed regimen [9]. Of necessity, we used the
authors' definitions, but when possible, we also included asfailures ongoing pregnancies that were continued at the
patient's choice after ingestion of mifepristone.
In abstracting data about protocols and study popula-
tions, we combined the original authors' categories that
were similar but not necessarily identical; for example, in
recording gestational age ranges, we considered “b63
days”, “≤63 days”, “b9 weeks”, and “≤9 weeks” all to
be equivalent, and we considered subjects who had had
no live births to be nulliparous if the report did not
describe parity (including both live births and stillbirths).
In recording parity and the gestational age distribution,
we accepted figures for either the entire enrolled trial
population or the analyzed population, as provided by the
authors. We used our judgment to resolve internal
inconsistencies and to correct frank errors noted in a
few reports.
Our analysis considered each group from each trial
(regardless of study design) as a separate case-series. We
combined data across trial groups to calculate the
proportion of subjects who had medical abortion failure
and the proportion who had ongoing pregnancy. We used
exact Pearson chi-square goodness-of-fit tests, calculated
using StatXact, Version 8.0 (Cytel Inc., Cambridge, MA,
USA), to assess heterogeneity across trial groups in both
outcomes. To explore possible explanations for heteroge-
neity, we used logistic regression to examine associations
between selected characteristics of the trial groups and,
separately, medical abortion failure rate and ongoing
pregnancy rate. The models controlled for nesting of
groups within trial using generalized estimating equations
with an independence working correlation matrix. The
response for the models was the ratio of the number of
events to the number of evaluable patients for each trial
group (conducted in SAS, version 9.2, SAS Institute, Cary
NC, USA); thus, model results were weighted by trial
group sample size. We used “missing” categories to
include trial groups with missing predictor data wherever
relevant. The models included interaction terms for
misoprostol dose and route of first dose. We excluded
from both models one trial group of 4 women treated with
200 mcg misoprostol [10]. We excluded from the ongoing
pregnancy model 3 trial groups in which ongoing
pregnancy was not assessed [11–13], and to allow model
convergence, we also excluded 4 groups in which women
received misoprostol 600 mcg sublingual [14–17] because
no ongoing pregnancies occurred in any groups with that
dose/route combination. For one study in which the
misoprostol dose was increased from 400 to 800 mcg
partway through [18], we estimated the number of women
and events in each of the two respective trial groups by
assuming that the enrollment rate was constant over the
course of the study. In reviewing the results, we focused
on associations that were both substantial (odds ratio N1.5
or b0.67) and significant (pb.05).
A previously published protocol for this systematic
review does not exist.
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The Medline search yielded 860 citations. Of these, 81
included at least one group of women who were treated
with an abortion regimen that used 200 mg mifepristone
followed by misoprostol in viable first trimester preg-
nancy [8–88]. In addition, we became aware of six
reports of unpublished trials (M. Pena and S. Raghavan,
Gynuity Health Projects, personal communication) that
met these criteria.
The 87 trials included 36 randomized trials and 51
prospective cohort or case series studies conducted at 314
sites in 35 countries (Table 1). Sixty-three of the trials were
performed between 1994 and 2011; the other 24 reports did
not provide dates of data collection. Inclusion criteria for the
trials were similar and broad: in general, any woman who
requested medical abortion, did not have contraindications to
the abortion drugs, and was within a specified gestational age
range (determined by ultrasound or clinically) was eligible.
Some trials had age restrictions and/or excluded women with
multiple gestations.
The 87 trials included 120 groups of women treated with
a regimen of interest: 62 trials studied a single such regimen,
18 studied two, six studied three, and one studied four
(Appendix). The total prescribed dose of misoprostol in the
regimens studied varied from 200–6400 mcg. In most trial
groups, the misoprostol was delivered in one administration,
but 13 groups received the total dose in divided increments
over 1–7 days. Routes of administration included vaginal,
oral, buccal and sublingual. The two most commonly
studied regimens used 800 mcg misoprostol vaginally or
400 mcg orally. The interval between the mifepristone and
the misoprostol ranged from 0 to 72 h. Some protocols
required that all subjects receive the misoprostol in the
clinic, whereas others allowed most or all women to take the
misoprostol at home. In nearly half the groups, the treatment
protocol specified that selected subjects who did not abort
after the initial treatment should be offered one or more
additional doses of misoprostol rather than immediate
surgical evacuation.
The timing of the initial follow-up evaluation of abortion
success varied from 1–21 days after mifepristone adminis-
tration. In about half the trial groups, ultrasound was used
routinely at the follow-up visit to determine whether the
medical abortion regimen resulted in complete abortion and,
if not, whether the pregnancy was ongoing. In other groups,
outcome assessment, including the diagnosis of ongoing
pregnancy, relied primarily or solely on patient symptoms
and/or clinical examination. Some trials allowed collection
of outcome information by telephone or by review of outside
records. No trial had explicit criteria for hospitalization and
transfusion of subjects.
The 120 trial groups included a total of 47,283 treated
subjects, of whom 45,528 (96%) provided evaluable data for
our effectiveness analyses (Table 1). The median proportion
of treated subjects with missing outcome data was 1.3%(range 0–19%). The number of evaluable subjects in the 120
groups ranged from 4 to 4,132.
Among all evaluable subjects, 2,192 (4.8%) had medical
abortion failure (Table 2). Across trial groups, the proportion
with this outcome ranged from 0 to 40% (Fig. 1A). Half the
groups had failure rates of 4.8% or less, and more than 90%
of the evaluable subjects were in trial groups in which the
failure proportion was 8.8% or less.
In 84 trials (117 groups), researchers noted whether or not
each patient with medical abortion failure was diagnosed
with ongoing pregnancy at the time of the failure
ascertainment (Table 2). Of the 45,150 evaluable subjects
in these trials, 499 (1.1%) had ongoing pregnancies. Across
these groups, the median percentage of subjects with
ongoing pregnancies was 0.7%, and 90% of the subjects
were in groups in which less than 2.9% of subjects had
ongoing pregnancy (Fig. 1B). The 499 ongoing pregnancies
constituted 23% of the 1,976 medical abortion failures in
these groups.
We found strong evidence of heterogeneity across trial
groups in both the proportion of subjects who had medical
abortion failure and the proportion who had ongoing
pregnancy (pb.001 for both outcomes). Logistic regression
models included as independent variables all the character-
istics listed in Table 2. These models found few associations
that were both substantial and significant. After adjustment
for other characteristics included in the model, groups in
which at least 25% of the women were in the ninth week of
pregnancy had higher medical abortion failure rates than
groups in which fewer women were so advanced in gestation
(OR 1.5; 95% CI 1.1–2.0). Groups instructed to take the
misoprostol b23 h after the mifepristone also had higher
medical abortion failure rates than other groups (OR 2.1;
95% CI 1.4–3.2). At each total misoprostol dose level, oral
administration was associated with higher medical abortion
failure rates than each of the other three routes, but no
substantial differences were noted among the other routes.
Similarly, for each route, 400 mcg misoprostol was
associated with higher failure rates than higher doses,
although not all of these associations were significant.
Associations of misoprostol dose and route with ongoing
pregnancy were mostly consistent with the associations with
failure of all types; that is, both the oral route and the 400
mcg dose of misoprostol were generally associated with
higher ongoing pregnancy rates than other doses and other
routes. Ongoing pregnancy was twice as common in groups
in which ultrasound was not routinely used to confirm
success than in groups in which it was used in all women
(OR 2.0, 95% CI 1.0–3.9). No notable associations were
apparent between ongoing pregnancy rates and of any of the
other group characteristics, however.
Across all trials, 119 of 45,528 evaluable subjects (0.3%)
were hospitalized; of these, 46 hospitalizations (38%)
occurred in a single trial [21] which included 4,132 treated
women. Most of the hospitalizations were for vaginal
bleeding, pelvic pain, or infection; some were for ectopic
Table 1
Characteristics of trial groups, subjects, medical abortion failures and ongoing pregnancies
Trial groupsa Evaluable subjectsa Abortion failure Ongoing pregnancy
N=120 (117) N=45,528 (45,150) N=2,192 N=499
n n n %b n %b
Study design
Randomized trial 65 22,768 1,172 5.1 230 1.0
Cohort or case-series study 55 (52) 22,760 (22,382) 1,020 4.5 269 1.2
Data collection datesc
Before mifepristone registration 42 (41) 13,859 (13,608) 744 5.4 140 1.0
After mifepristone registration 44 (42) 22,029 (21,902) 864 3.9 245 1.1
Missing 34 9,640 584 6.1 114 1.2
Geographic region
Europe 31 (30) 10,772 (10,745) 378 3.5 88 0.8
Americas 36 16,598 564 3.4 123 0.7
Other 53 (51) 18,158 (17,807) 1,250 6.9 288 1.6
Number of study sites
1 59 (57) 12,071 (11,944) 452 3.7 102 0.9
N1 61 (60) 33,457 (33,206) 1,740 5.2 397 1.2
Prescribed interval between mifepristone and misoprostol
b23 h 11 2,018 108 5.4 20 1.0
23–72 h 109 (106) 43,510 (43,132) 2,084 4.8 479 1.1
Protocol specified additional dose of misoprostol for selected subjects
No 67 (64) 20,512 (20,134) 1,335 6.5 276 1.4
Yes 53 25,016 857 3.4 223 0.9
Protocol required all subjects to take misoprostol in clinic
No 56 (55) 24,921 (24,894) 1,132 4.5 306 1.2
Yes 57 (56) 18,007 (17,907) 930 5.2 178 1.0
Not stated 7 (6) 2,600 (2,349) 130 5.0 15 0.6
Minimum scheduled follow-up interval
b1 week 36 15,343 485 3.2 90 0.6
≥1 week 84 (81) 30,185 (29,807) 1,707 5.7 409 1.4
Protocol required ultrasound to assess failure
In none or some subjects 51 (50) 26,505 (26,478) 1,472 5.6 365 1.4
In all subjects 64 (63) 18,046 (17,946) 647 3.6 121 0.7
Not stated 5 (4) 977 (726) 73 7.5 13 1.8
% of population who were nulliparous
N50% 34 (33) 15,522 (15,271) 563 3.6 89 0.6
≤50% 40 (39) 16,378 (16,278) 838 5.1 203 1.2
Missing 46 (45) 13,628 (13,601) 791 5.8 207 1.5
% of population with gestational age N56 days
N25% 16 8,579 506 5.9 87 1.0
≤25% 84 (82) 33,123 (32,996) 1,506 4.5 380 1.2
Missing 20 (19) 3,826 (3,575) 180 4.7 32 0.9
Misoprostol dose and routed
200 mcg oral 1 4 1 25.0 1 25.0
400 mcg buccal 1 272 8 2.9 4 1.5
400 mcg oral 21 9,299 737 7.9 215 2.3
400 mcg sublingual 10 2,875 126 4.4 30 1.0
400 mcg vaginal 5 1,116 86 7.7 20 1.8
600 mcg oral 9 1,608 132 8.2 22 1.4
600 mcg sublingual 4 540 7 1.3 0 0.0
600 mcg vaginal 1 242 18 7.4 9 3.7
≥800 mcg buccal 6 2,205 71 3.2 16 0.7
≥800 mcg oral 10 (8) 2449 (2,322) 158 6.5 38 1.6
≥800 mcg sublingual 4 1,003 52 5.2 5 0.5
≥800 mcg vaginal 43 (42) 19,210 (18,959) 653 3.4 99 0.5
Varied or missing 5 4,705 143 3.0 40 0.9
a Number in all groups (number in groups in which ongoing pregnancy was reported, if different).
b Percent of subjects in trial groups reporting outcome.
c Dates of mifepristone registration in each country obtained fromwww.gynuity.org, accessed 17August 2011. Coded as “before mifepristone registration” if the
year that data collection ended was not more than 1 year after the registration year and otherwise as “after” if the data collection started in the year after the registration
year or later. This variable is missing for trials conducted in multiple countries and studies that provided insufficient information about dates of data collection.
d Total misoprostol dose and route of first dose if multiple doses were administered.
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Table 2
Associations between trial and population characteristics and rates of







OR (95% CI) OR (95% CI)
Group size: each increase of
500 women
1.0 (0.9–1.1) 1.0 (0.9–1.2)
Study design
Randomized trial 1.1 (0.9–1.4) 1.2 (0.8–1.9)
Cohort or case-series study 1 1
Data collection datesb
Before mifepristone registration 1.2 (0.8–1.6) 0.7 (0.3–1.5)
After mifepristone registration 1 1
Geographic region
Europe 0.7 (0.4–1.3) 0.6 (0.3–1.3)
Americas 1 1
Other 1.0 (0.7–1.5) 0.9 (0.4–1.7)
Number of study sites
1 0.9 (0.7–1.3) 0.8 (0.5–1.2)
N1 1 1
Prescribed interval between mifepristone and misoprostol
b23 h 2.1 (1.4–3.2) 1.2 (0.5–2.9)
23-72 h 1 1
Protocol specified additional dose of misoprostol for selected subjects
Yes 0.7 (0.5–1.1) 1.1 (0.6–2.0)
No 1 1
Protocol required all subjects to take misoprostol in clinic
No 0.9 (0.7–1.2) 1.3 (0.7–2.7)
Yes 1 1
Minimum scheduled follow-up interval
b1 week 0.9 (0.7–1.2) 1.4 (0.6–3.0)
≥1 week 1 1
Protocol required ultrasound to assess failure
Never or in selected subjects 1.1 (0.7–1.7) 2.0 (1.0–3.9)
In all subjects 1 1
% of population who were nulliparous
N50% 1.1 (0.9–1.4) 0.8 (0.5–1.3)
≤50% 1 1
% of population with gestational age N56 days
N25% 1.5 (1.1–2.0) 0.9 (0.6–1.6)
≤25% 1 1
Lost to follow-up %: each 1%
increase
0.6 (0.0–25.2) 5.9 (0.0–4,524)
Misoprostol route by dosec
400 mcg
Sublingual 0.5 (0.4–0.7) 0.5 (0.3–0.7)
Buccal 0.5 (0.3–0.8) 0.5 (0.2–1.0)
Vaginal 0.6 (0.4–1.0) 0.7 (0.4–1.3)
Oral 1 1
600 mcg
Sublingual 0.2 (0.1–0.3) –
Vaginal 0.5 (0.2–0.9) 4.6 (1.2–18.0)
Oral 1 1
≥800 mcg
Sublingual 0.6 (0.4–0.9) 0.3 (0.2–0.6)
Buccal 0.6 (0.4–0.9) 0.3 (0.2–0.6)
Vaginal 0.6 (0.5–0.8) 0.4 (0.3–0.6)
Oral 1 1
Misoprostol dose by routec
Oral route
≥800 mcg 0.7 (0.5–0.9) 0.6 (0.3–1.1)
600 mcg 0.9 (0.7–1.3) 0.6 (0.3–1.2)








OR (95% CI) OR (95% CI)
Vaginal route
≥800 mcg 0.6 (0.4–0.9) 0.3 (0.2–0.6)
600 mcg 0.7 (0.4–1.2) 3.6 (1.2–11.5)
400 mcg 1 1
Sublingual route
≥800 mcg 0.8 (0.6–1.1) 0.4 (0.2–0.8)
600 mcg 0.3 (0.2–0.6) –
400 mcg 1 1
Buccal route
≥800 mcg 0.7 (0.5–1.2) 0.4 (0.2–0.8)
400 mcg 1 1
a Analyses of medical abortion failure used 119 trial groups; analyses of
ngoing pregnancy used 112 trial groups (see text).
b Dates of mifepristone registration in each country obtained from
ww.gynuity.org, accessed 17 August 2011. Coded as “before mifepristone
gistration” if the year that data collection ended was not more than 1 year
fter the registration year and otherwise as “after” if the data collection
tarted in the year after the registration year or later. This variable is missing
r trials conducted in multiple countries and studies that provided
sufficient information about dates of data collection.
c Total misoprostol dose and route of first dose if multiple doses were
dministered.








apregnancy or other conditions unrelated to the abortion.
Forty-five women (0.1%) received blood transfusions.
Hospitalizations and blood transfusions were less common
in trials in which women were permitted to take the
misoprostol at home (0.15% and 0.08%, respectively) than
in trials in which clinic administration was required (0.45%
and 0.14%, respectively).4. Discussion
Medical abortion using mifepristone 200 mg followed by
misoprostol in the first 63 days of gestation is remarkably
effective and safe. In trials that together included more than
45,000 women conducted in disparate settings over nearly
two decades using a variety of regimens and treatment
protocols, fewer than 5% of subjects required surgery to
complete termination of the pregnancy. The proportion who
had ongoing pregnancy at follow-up — the outcome of
greatest concern to clinicians — was 1.1%. Serious
complications requiring hospitalization or transfusion oc-
curred in less than 0.4% of patients.
Some random variability in results is expected in any
collection of research studies. However, our analysis found
strong evidence of statistical heterogeneity across trials in
both medical abortion failure rates and rates of ongoing
pregnancy. This finding indicates that the non-uniformity in
these outcomes was due to underlying differences among the
studies rather than simply to chance. We identified a few
practices that were associated with a lower risk of medical
AB
Fig. 1. Size of trial group by percentage of subjects with medical abortion failure and ongoing pregnancy at follow-up assessment. 50% of trial groups are to the
left of dashed line; 90% of subjects are to the left of solid line. One group of 4 subjects with one ongoing pregnancy is omitted from both panels; panel A also
omits one group of 20 subjects with 8 medical abortion failures. (A) Medical abortion failure. (B) Ongoing pregnancy.
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mifepristone and misoprostol, use of misoprostol doses
higher than 400 mcg and administration of misoprostol by a
buccal, vaginal, or sublingual rather than oral route. The last
of these is consistent with the conclusions of a recent
Cochrane review of first trimester medical abortion, which
included only randomized trials [89]. As cited previously,
most current guidelines for medical abortion incorporate
these practices.
We also found slightly higher risks of medical abortion
failure in groups that had a high proportion (N25%) of
women in the 9th week of pregnancy: after adjustment for
other factors, these groups overall had a 50% higher odds ofmedical abortion failure. However, we did not find a higher
risk of ongoing pregnancy in these groups. Given the low
overall risk of medical abortion failure and the relative ease
of treating failure using surgical evacuation (which would
have been the treatment for all subjects had medical abortion
not been attempted), offering medical abortion to women at
this gestational age seems reasonable.
We observed no significant association between abortion
failure rates and the timing of the follow-up evaluation. The
data thus are inconclusive with respect to the theory that high
surgical intervention rates are in part attributable to
impatience among providers and patients [90]. Moreover,
although routine ultrasound evaluation at follow-up was
32 E.G. Raymond et al. / Contraception 87 (2013) 26–37associated with a lower risk of diagnosis of ongoing
pregnancy, we found no evidence for or against an effect
of this practice on overall medical abortion failure rates —
that is, the need for surgical intervention. Prompt confirma-
tion of completeness of the abortion and clinical assessment
without routine ultrasound may enhance women's satisfac-
tion with the procedure.
We found no evidence that allowing women to take the
misoprostol at home increased the rates of abortion failure or
serious complications. Most women prefer this option [90],
and it is presumably substantially more efficient for the health
care system than requiring patients to return to the provider
for administration of the prostaglandin. This requirement,
which is law in some countries such as the United Kingdom
[7], thus is unjustifiable and should be abandoned.
This analysis has some limitations. Our data allowed us
to explore heterogeneity across patient populations, not
across individual patients; therefore, we may have missed
some associations that would have been identified in an
individual-level analysis. Missing data on some character-
istics of some groups may have affected the direction or
strength of associations, and we acknowledge that including
“missing” categories for predictor variables would not have
been preferred had we analyzed individual-level data [91].
Because none of the 540 women in the four groups that
received misoprostol 600 mcg sublingual had ongoing
pregnancies, these groups were excluded for technical
reasons from our regression analysis of that outcome; this
omission may have affected the apparent associations of
other factors with ongoing pregnancy. Undetected publica-tion bias is always possible; we attempted to minimize this
problem by consulting experts likely to be aware of relevant
unpublished studies through their many years of work in
this field. We had information on only selected character-
istics of the studies, and unmeasured confounding was not
controlled by randomization. We evaluated many potential
associations without any adjustment for multiple compar-
isons; however, we fit only a single model for each
outcome. In 5 of the 120 trial groups, at least 10% of
subjects were lost to follow-up. However, the overall
follow-up success was high, and even if we made the
extreme assumption that all the subjects who were lost had
abortion failures, the overall medical abortion failure rate
would still have been low (8.3%).
The large quantity of data presented in this review
demonstrates that currently used medical abortion regimens
are so effective and safe that additional research aimed at
further clinical improvement will have little public health
benefit. Future investigations should focus on service
delivery issues: increasing access, reducing cost, enhancing
patient comfort and ensuring availability of ancillary services
such as contraception that can aid women in reaching their
reproductive goals.Acknowledgments
Financial support for this review was provided by an
anonymous charitable foundation.
Reprints will not be available.Appendix. Selected data from 120 trial groupsRef Country Date Dose/route Delay Treated Evaluable Medical
abortion
failureOngoing
pregnancyN N N % N %11 Ethiopia 2009 800 mg vag 48 251 251 13 5.2 n/a n/a
87 USA 2006–2007 800 mg buc 24 to 36 482 421 16 3.8 4 1.0
87 USA 2006–2007 800 mg oral 24 to 36 480 426 37 8.7 15 3.5
86 Nepal 2009–2010 800 mg vag 48 1077 1032 34 3.3 5 0.5
85 Multiple 2003–2005 800 mg vag 48 545 532 40 7.5 4 0.8
85 Multiple 2003–2005 800 mg vag 24 542 529 32 6.0 4 0.8
84 Multiple 2007–2008 400 mg SL 24 751 741 63 8.5 14 1.9
84 Multiple 2007–2008 400 mg vag 24 751 738 77 10.4 18 2.4
84 Multiple 2007–2008 800 mg SL 24 752 739 45 6.1 4 0.5
84 Multiple 2007–2008 800 mg vag 24 751 744 41 5.5 8 1.1
83 Multiple 1998–2000 800 mg oral then 400 mg oral bid×7 d 36 to 48 740 730 47 6.4 9 1.2
83 Multiple 1998–2000 800 mg vag then 400 mg oral bid×7 d 36 to 48 741 731 29 4.0 1 0.1
83 Multiple 1998–2000 800 mg vag 36 to 48 738 729 39 5.3 2 0.3
82 Taiwan 2000 400 mg, route n/a 48 20 20 8 40.0 1 5.0
82 Taiwan 2000 600 mg, route n/a 48 20 20 3 15.0 2 10.0
81 N. Korea 2007–2008 400 mg SL 48 199 199 8 4.0 0 0.0
80 UK n/a 600 mg oral 48 100 100 8 8.0 3 3.0
79 China n/a 400 mg vag 48 100 98 3 3.1 1 1.0
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pregnancyN N N % N %78 China n/a 800 mg SL 48 100 99 5 5.1 1 1.0
77 China n/a 800 mg oral then 400 mg oral bid×7 d 48 50 48 3 6.3 0 0.0
77 China n/a 800 mg vag then 400 mg oral bid×7 d 48 50 50 3 6.0 2 4.0
77 China n/a 800 mg vag 48 50 47 1 2.1 0 0.0
76 China n/a 400 mg vag 48 200 200 3 1.5 1 0.5
75 China n/a 400 mg vag then 400 mg oral bid×14 d 48 20 20 0 0.0 0 0.0
74 China n/a 800 mg SL 48 112 112 2 1.8 0 0.0
74 China n/a 800 mg vag 48 112 112 7 6.3 3 2.7
73 India n/a 600 mg oral 48 51 50 11 22.0 0 0.0
14 India n/a 200 mg SL×3 q6h 24 40 40 0 0.0 0 0.0
72 Nepal 2009 600 mg oral 48 50 50 3 6.0 0 0.0
71 USA 2001–2003 400 mg oral 48 376 354 30 8.5 13 3.7
70 Canada 2001 400 mg oral 24 to 48 319 319 17 5.3 0 0.0
70 Canada 2001 600 mg oral 24 to 48 319 317 21 6.6 1 0.3
70 Canada 2001 800 mg vag 24 to 48 318 317 18 5.7 0 0.0
69 USA n/a 800 mg vag 0 80 80 7 8.8 0 0.0
66 USA 1998–1999 800 mg vag 24 745 708 15 2.1 5 0.7
66 USA 1998–1999 800 mg vag 72 772 699 28 4.0 8 1.1
66 USA 1998–1999 800 mg vag 48 778 745 16 2.1 3 0.4
67 USA 2000 400 mg oral×2 q2h 48 279 270 15 5.6 2 0.7
67 USA 2000 400 mg oral 48 228 223 21 9.4 2 0.9
67 USA 2000 800 mg vag 48 538 528 12 2.3 2 0.4
68 USA 1999–2000 400 mg oral×2 q2h 24 561 548 29 5.3 6 1.1
68 USA 1999–2000 800 mg vag 24 607 596 4 0.7 0 0.0
65 USA 1997–1999 800 mg vag 48 1137 1121 34 3.0 5 0.4
64 USA 1999 800 mg vag 48 30 27 2 7.4 2 7.4
63 USA 1996–1997 800 mg vag 48 933 928 21 2.3 6 0.6
62 China n/a 600 mg oral 48 149 148 7 4.7 3 2.0
61 Moldova 2005–2006 400 mg oral 24 240 233 14 6.0 5 2.1
61 Moldova 2005–2006 400 mg SL 24 240 238 3 1.3 1 0.4
60 Moldova 2007–2009 400 mg buc 24 277 272 8 2.9 4 1.5
60 Moldova 2007–2009 400 mg SL 24 273 267 7 2.6 4 1.5
59 USA n/a 800 mg vag 6 to 8 40 40 1 2.5 0 0.0
58 USA 1998–2000 800 mg vag 48 28 28 0 0.0 0 0.0
57 USA 2008 800 mg vag or buc 0 to 72 139 135 8 5.9 4 3.0
10 UK n/a 200 mg oral 48 4 4 1 25.0 1 25.0
10 UK n/a 400 mg oral 48 10 10 2 20.0 1 10.0
10 UK n/a 600 mg oral 48 7 7 0 0.0 0 0.0
56 Vietnam 2001 400 mg oral 48 1601 1577 182 11.5 44 2.8
55 Vietnam 2007–2008 800 mg buc 24 201 201 7 3.5 3 1.5
54 USA 2003 800 mg vag 0 40 40 2 5.0 0 0.0
53 India 2004–2005 400 mg SL 48 149 144 2 1.4 1 0.7
52 USA 2001–2004 800 mg buc 24 to 48 223 216 11 5.1 2 0.9
52 USA 2001–2004 800 mg vag 24 to 48 219 213 14 6.6 4 1.9
51 UK n/a 600 mg oral 48 110 110 7 6.4 1 0.9
50 USA 2006 800 mg buc 0 120 117 5 4.3 0 0.0
15 Taiwan 2002–2005 600 mg SL 48 356 355 5 1.4 0 0.0
49 Taiwan 2005–2009 600 mg vag 0 254 242 18 7.4 9 3.7
48 Taiwan 2005–2006 800 mg vag 0 90 90 2 2.2 0 0.0
47 Sweden 2004–2007 800 mg vag 36 to 48 395 395 10 2.5 4 1.0
46 Nepal 2007–2008 400 mg oral 48 400 367 32 8.7 9 2.5
45 USA n/a 800 mg vag 48 125 121 5 4.1 0 0.0
18 Finland 2000–2002 400 or 800 mg vag 24, 48, or 72 1289 1238 67 5.4 9 0.7
16 UK 2002–2003 600 mg SL 36 to 48 49 49 1 2.0 0 0.0
44 UK 2002–2003 600 mg SL then 400 mg SL 3 h later 36 to 48 57 53 0 0.0 0 0.0
44 UK 2002–2003 800 mg vag then 400 mg vag 3 h later 36 to 48 72 69 1 1.4 0 0.0
17 UK n/a 600 mg SL 36 to 48 96 96 1 1.0 0 0.0
17 UK n/a 800 mg vag 36 to 48 53 53 2 3.8 0 0.0
43 Tunisia 2000–2001 400 mg oral 48 332 323 14 4.3 5 1.5(continued on next page)
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pregnancyN N N % N %42 UK 2003–2005 800 mg vag 6 210 210 21 10.0 5 2.4
42 UK 2003–2005 800 mg vag 36 to 48 215 215 8 3.7 3 1.4
41 India 2009–2010 400 mg vag 0 40 40 2 5.0 0 0.0
41 India 2009–2010 400 mg vag 24 40 40 1 2.5 0 0.0
40 USA n/a 800 mg vag 6 to 8 80 80 1 1.3 0 0.0
39 Tunisia 2007–2008 400 mg oral 48 126 126 7 5.6 1 0.8
38 Vietnam, Tunisia 1997–1998 400 mg oral 48 315 306 25 8.2 4 1.3
37 UK n/a 400 mg oral×2 q2h 36 to 48 75 75 6 8.0 3 4.0
37 UK n/a 800 mg oral 36 to 48 75 75 4 5.3 2 2.7
36 USA 1998–1999 800 mg vag 24, 48, or 72 138 138 4 2.9 0 0.0
8 India n/a 400 mg oral 24 48 48 6 12.5 1 2.1
8 India n/a 400 mg SL 24 45 45 2 4.4 0 0.0
35 India n/a 800 mg vag 48 50 50 1 2.0 0 0.0
34 USA 2004–2006 800 mg vag 0 567 554 27 4.9 4 0.7
34 USA 2004–2006 800 mg vag 23 to 25 561 546 17 3.1 1 0.2
33 USA 2000–2001 800 mg vag 24 to 48 148 145 5 3.4 0 0.0
9 USA 2002–2003 800 mg vag 23 to 25 539 531 10 1.9 1 0.2
9 USA 2002–2003 800 mg vag 6 to 8 539 525 22 4.2 2 0.4
32 India 2004–2005 400 mg oral×2 q3h 48 150 150 12 8.0 1 0.7
32 India 2004–2005 400 mg oral 48 150 147 20 13.6 10 6.8
12 France 2001–2002 400 mg oral×2 q24h 24 30 27 1 3.7 n/a n/a
31 USA 2005–2007 800 mg vag, oral or buc 6 to 72 4087 3292 57 1.7 24 0.7
30 Nepal 2004–2005 400 mg oral 48 112 107 16 15.0 2 1.9
29 Nepal 2005–2006 800 mg vag 48 50 50 3 6.0 0 0.0
27 Albania 2001–2003 400 mg oral 48 409 404 12 3.0 3 0.7
28 India 2007–2008 400 mg oral 48 599 574 60 10.5 5 0.9
26 Curacao 2009–2010 800 mg buc 24 to 36 304 281 6 2.1 1 0.4
25 Tunisia 1999–2000 400 mg oral 48 222 213 11 5.2 4 1.9
24 India n/a 600 mg oral 48 450 440 54 12.3 5 1.1
23 UK n/a 800 mg vag 48 500 459 6 1.3 1 0.2
22 UK n/a 600 mg oral 48 400 386 21 5.4 9 2.3
21 UK 1994–2001 800 mg vag 36 to 48 4132 4132 95 2.3 14 0.3
13 India 2003–2004 800 mg oral 24 100 100 4 4.0 n/a n/a
20 Turkey 2004–2005 400 mg oral 48 161 161 6 3.7 3 1.9
20 Turkey 2004–2005 400 mg SL 48 46 46 4 8.7 1 2.2
19 Turkey 2000–2001 400 mg oral 48 208 207 33 15.9 3 1.4
88 multiple n/a 400 mg oral 48 792 775 68 8.8 22 2.8
U1 Mexico 2010–2011 800 mg buc 24 to 48 998 969 26 2.7 6 0.6
U2 Ukraine 2005–2007 400 mg oral 48 439 436 13 3.0 4 0.9
U3 Uzbekistan 2008–2009 400 mg SL 24 450 450 21 4.7 5 1.1
U4 Moldova 2007 400 mg SL 24 300 295 8 2.7 1 0.3
U5 Vietnam 2006–2008 400 mg oral 48 2400 2389 148 6.2 74 3.1
U6 Ukraine 2007–2009 400 mg SL 24 450 450 8 1.8 3 0.7n/a: data not available.
Ref indicates reference number. U1-U6 are unpublished studies.
Date indicates dates of data collection.
Dose/route indicates dose and route of misoprostol. SL, sublingual; vag, vaginal; buc, buccal; q, every; h, hours; d, days.
Delay indicates prescribed interval between mifepristone and misoprostol, in hours.
Evaluable indicates number of subjects with known abortion outcome.
Failures indicates number and percent of evaluable subjects with abortion failure.
Ongoing pregnancy indicates number and percent of evaluable subjects with abortion failures that were ongoing pregnancies.References[1] Jones RK, Kooistra K. Abortion incidence and access to services in
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